% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Joshi:182834,
      author       = {S. Joshi and D. Anantharaman and R. Muwonge and N. Bhatla
                      and G. Panicker and J. A. Butt$^*$ and U. Rani Reddy Poli
                      and S. G. Malvi and P. O. Esmy and E. Lucas and Y. Verma and
                      A. Shah and E. Zomawia and S. Pimple and K. Jayant and S.
                      Hingmire and A. Chiwate and U. Divate and S. Vashist and G.
                      Mishra and R. Jadhav and M. Siddiqi and S. Sankaran and T.
                      Pillai Rameshwari Ammal Kannan and P. Kartha and S. S.
                      Shastri and C. Sauvaget and M. Radhakrishna Pillai and T.
                      Waterboer$^*$ and M. Müller$^*$ and P. Sehr$^*$ and E. R.
                      Unger and R. Sankaranarayanan and P. Basu},
      title        = {{E}valuation of immune response to single dose of
                      quadrivalent {HPV} vaccine at 10-year post-vaccination.},
      journal      = {Vaccine},
      volume       = {1},
      number       = {4},
      issn         = {0264-410X},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2022-02961},
      pages        = {236-245},
      year         = {2023},
      note         = {Volume 41, Issue 1, 4 January 2023, Pages 236-245},
      abstract     = {The recent World Health Organization recommendation
                      supporting single-dose of HPV vaccine will significantly
                      reduce programmatic cost, mitigate the supply shortage, and
                      simplify logistics, thus allowing more low- and
                      middle-income countries to introduce the vaccine. From a
                      programmatic perspective the durability of protection
                      offered by a single-dose will be a key consideration. The
                      primary objectives of the present study were to determine
                      whether recipients of a single-dose of quadrivalent HPV
                      vaccine had sustained immune response against targeted HPV
                      types (HPV 6,11,16,18) at 10 years post-vaccination and
                      whether this response was superior to the natural antibody
                      titres observed in unvaccinated women.Participants received
                      at age 10-18 years either one, two or three doses of the
                      quadrivalent HPV vaccine. Serology samples were obtained at
                      different timepoints up to 10 years after vaccination from a
                      convenience sample of vaccinated participants and from
                      age-matched unvaccinated women at one timepoint. The
                      evolution of the binding and neutralizing antibody response
                      was presented by dose received. 10-year durability of immune
                      responses induced by a single-dose was compared to that
                      after three doses of the vaccine and in unvaccinated married
                      women.The dynamics of antibody response among the
                      single-dose recipients observed over 120 months show
                      stabilized levels 18 months after vaccination for all four
                      HPV types. Although the HPV type-specific (binding or
                      neutralizing) antibody titres after a single-dose were
                      significantly inferior to those after three doses of the
                      vaccine (lower bounds of GMT ratios < 0.5), they were all
                      significantly higher than those observed in unvaccinated
                      women following natural infections (GMT ratios: 2.05 to
                      4.04-fold higher). The results correlate well with the high
                      vaccine efficacy of single-dose against persistent HPV 16/18
                      infections reported by us earlier at 10-years
                      post-vaccination.Our study demonstrates the high and durable
                      immune response in single-dose recipients of HPV vaccine at
                      10-years post vaccination.},
      keywords     = {Human papillomavirus (Other) / Natural immunity (Other) /
                      Single dose (Other) / Vaccine immune responses (Other) /
                      quadrivalent HPV vaccine (Other)},
      cin          = {F020 / W040},
      ddc          = {610},
      cid          = {I:(DE-He78)F020-20160331 / I:(DE-He78)W040-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36446654},
      doi          = {10.1016/j.vaccine.2022.11.044},
      url          = {https://inrepo02.dkfz.de/record/182834},
}